Severe asthma and fungi: Current evidence

Medical Mycology

Volumn 49, Issue SUPPL. 1, 2011, Pages

  Agarwal, Ritesh ^a   Gupta, Dheeraj ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

ABPA; allergic bronchopulmonary aspergillosis; Aspergillus; asthma; azoles; severe asthma with fungal sensitization

Indexed keywords

ASTEMIZOLE; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CISAPRIDE; CORTICOSTEROID; FLUCONAZOLE; IMMUNOGLOBULIN E; ITRACONAZOLE; METHYLPREDNISOLONE; MONTELUKAST; OMALIZUMAB; PREDNISOLONE; TERFENADINE; THEOPHYLLINE;

ADD ON THERAPY; ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ALLERGIC ASTHMA; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ALLERGIC RHINITIS; ALTERNARIA; ASPERGILLUS; ASPERGILLUS HYPERSENSITIVITY; ASTHMA; CANDIDA; CLADOSPORIUM; CONFERENCE PAPER; DRUG INHIBITION; DRUG MECHANISM; FUNGUS; FUNGUS SPORE; HEART ARRHYTHMIA; HUMAN; HYPERSENSITIVITY; HYPHOMYCETES; NONHUMAN; PEAK EXPIRATORY FLOW; PENICILLIUM; QUALITY OF LIFE; SEVERE ASTHMA WITH FUNGAL SENSITIZATION; SIDE EFFECT; SKIN PRICK TEST; SKIN TEST; TRICHOPHYTON;

ALLERGENS; ANTIGENS, FUNGAL; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS; ASTHMA; FUNGI; HUMANS; SEVERITY OF ILLNESS INDEX;

ASPERGILLUS; FUNGI;

EID: 79952669906     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2010.504752     Document Type: Conference Paper

References (87)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Available with 2009 update from: http:// www.ginasthma.com/Guidelineitem.aspl1 =2&l2=1&intId= 1561
2. Reddy RC. Severe asthma: approach and management. Postgrad Med J 2008; 84: 115-120; quiz 119. (Pubitemid 351498007)
3. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005; 172: 149-160. (Pubitemid 40981187)
4. Papiris S, Kotanidou A, Malagari K, Roussos C. Clinical review: severe asthma. Crit Care 2002; 6: 30-44. (Pubitemid 34162856)
5. Herbert FA, Weimer N, Salkie ML. RAST and skin test screening in the investigation of asthma. Ann Allergy 1982; 49: 311-314. (Pubitemid 13204179)
6. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320: 271-277. (Pubitemid 19045550)
7. Kalliel JN, Goldstein BM, Braman SS, Settipane GA. High frequency of atopic asthma in a pulmonary clinic population. Chest 1989; 96: 1336-1340. (Pubitemid 20000832)
8. Miles J, Cayton R, Ayres J. Atopic status in patients with brittle and non-brittle asthma: a case-control study. Clin Exp Allergy 1995; 25: 1074-1082.
9. Langley SJ, Goldthorpe S, Craven M, et al. Exposure and sensitiza-tion to indoor allergens: association with lung function, bronchial reactivity, and exhaled nitric oxide measures in asthma. J Allergy Clin Immunol 2003; 112: 362-368. (Pubitemid 36981377)
10. Woodcock A, Forster L, Matthews E, et al. Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma. N Engl J Med 2003; 349: 225-236. (Pubitemid 36859474)
11. Denning DW, O'Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006; 27: 615-626. (Pubitemid 43372538)
12. Neas LM, Dockery DW, Burge H, Koutrakis P, Speizer FE. Fungus spores, air pollutants, and other determinants of peak expiratory f ow rate in children. Am J Epidemiol 1996; 143: 797-807. (Pubitemid 26119824)
13. Delf no RJ, Zeiger RS, Seltzer JM, et al. The effect of outdoor fungal spore concentrations on daily asthma severity. Environ Health Perspect 1997; 105: 622-635.
14. Salvaggio J, Seabury J, Schoenhardt FA. New Orleans asthma. V. Relationship between Charity Hospital asthma admission rates, semiquantitative pollen and fungal spore counts, and total particulate aerometric sampling data. J Allergy Clin Immunol 1971; 48: 96-114.
15. Newson R, Strachan D, Corden J, Millington W. Fungal and other spore counts as predictors of admissions for asthma in the Trent region. Occupation Environ Med 2000; 57: 786-792.
16. Jenkins PF, Mullins JK, Davies BH, Williams DA. The possible role of aero-allergens in the epidemic of asthma deaths. Clin Allergy 1981; 11: 611-620. (Pubitemid 12172261)
17. Targonski PV, Persky VW, Ramekrishnan V. Effect of environmental molds on risk of death from asthma during the pollen season. J Allergy Clin Immunol 1995; 95: 955-961.
18. O'Hollaren M, Yunginger J, Offord K, et al. Exposure to an aeroal-lergen as a possible precipitating factor in respiratory arrest in young patients with asthma. N Engl J Med 1991; 324: 359-363.
19. Peat JK, Tovey E, Mellis CM, Leeder SR, Woolcock AJ. Importance of house dust mite and Alternaria allergens in childhood asthma: an epidemiological study in two climatic regions of Australia. Clin Exp Allergy 1993; 23: 812-820. (Pubitemid 23327375)
20. Nelson HS, Szef er SJ, Jacobs J, et al. The relationships among environmental allergen sensitization, allergen exposure, pulmonary function, and bronchial hyperresponsiveness in the Childhood Asthma Management Program. J Allergy Clin Immunol 1999; 104: 775-785. (Pubitemid 30249297)
21. Neukirch C, Henry C, Leynaert B, et al. Is sensitization to Alternaria alternata a risk factor for severe asthma? A population-based study. J Allergy Clin Immunol 1999; 103: 709-711. (Pubitemid 29295582)
22. Roux P, Smit M, Weinberg EG. Seasonal and recurrent intensive care unit admissions for acute severe asthma in children. S Afr Med J 1993; 83: 177-179. (Pubitemid 23128748)
23. Black PN, Udy AA, Brodie SM. Sensitivity to fungal allergens is a risk factor for life-threatening asthma. Allergy 2000; 55: 501-504. (Pubitemid 30230362)
24. Zureik M, Neukirch C, Leynaert B, et al. Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey. BMJ 2002; 325: 411-414. (Pubitemid 34969788)
25. O'Driscoll BR, Hopkinson LC, Denning DW. Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions. BMC Pulm Med 2005; 5: 4.
26. Niedoszytko M, Chelminska M, Jassem E, Czestochowska E. Association between sensitization to Aureobasidium pullulans (Pullularia sp) and severity of asthma. Ann Allergy Asthma Immunol 2007; 98: 153-156. (Pubitemid 46214220)
27. Matsuoka H, Niimi A, Matsumoto H, et al. Specific IgE response to trichophyton and asthma severity. Chest 2009; 135: 898-903.
28. Dolan CT, Weed LA, Dines DE. Bronchopulmonary helminthospo-riosis. Am J Clin Pathol 1970; 53: 235-242.
29. Sahn SA, Lakshminarayan S. Allergic bronchopulmonary penicillio-sis. Chest 1973; 63: 286-288.
30. Novey HS, Wells ID. Allergic bronchopulmonary aspergillosis caused by Aspergillus ochraceus. Am J Clin Pathol 1978; 70: 840-843. (Pubitemid 9071291)
31. Benatar SR, Allan B, Hewitson RP, Don PA. Allergic bronchopulmo-nary stemphyliosis. Thorax 1980; 35: 515-518.
32. Laham MN, Allen RC, Greene JC. Allergic bronchopulmonary asper-gillosis (ABPA) caused by Aspergillus terreus: specific lymphocyte sensitization and antigen-directed serum opsonic activity. Ann Allergy 1981; 46: 74-80. (Pubitemid 11090475)
33. McAleer R, Kroenert DB, Elder JL, Froudist JH. Allergic bron-chopulmonary disease caused by Curvularia lunata and Drechslera hawaiiensis. Thorax 1981; 36: 338-344. (Pubitemid 11105825)
34. Patterson R, Samuels BS, Phair JJ, Roberts M. Bronchopulmonary torulopsosis. Int Arch Allergy Appl Immunol 1982; 69: 30-33. (Pubitemid 12050077)
35. Kino T, Yamada Y, Honda K, et al. [Diagnosis and treatment of a case of allergic bronchopulmonary mycosis caused by Mucor-like fungus]. Nihon Kyobu Shikkan Gakkai Zasshi 1983; 21: 896-903. (Pubitemid 14246233)
36. Akiyama K, Mathison DA, Riker JB, Greenberger PA, Patterson R. Allergic bronchopulmonary candidiasis. Chest 1984; 85: 699-701. (Pubitemid 14147923)
37. Sharma TN, Gupta PR, Mehrotra AK, Purohit SD, Mangal HN. Aspergilloma with ABPA due to Aspergillus niger. J Assoc Physicians India 1985; 33: 748.
38. Lake FR, Tribe AE, McAleer R, Froudist J, Thompson PJ. Mixed allergic bronchopulmonary fungal disease due to Pseudallescheria boydii and Aspergillus. Thorax 1990; 45: 489-491. (Pubitemid 20225179)
39. Lake FR, Froudist JH, McAleer R, et al. Allergic bronchopulmonary fungal disease caused by Bipolaris and Curvularia. Aust N Z J Med 1991; 21: 871-874.
40. Kamei K, Unno H, Nagao K, et al. Allergic bronchopulmonary mycosis caused by the basidiomycetous fungus Schizophyllum commune. Clin Infect Dis 1994; 18: 305-309. (Pubitemid 24086295)
41. Backman KS, Roberts M, Patterson R. Allergic bronchopulmonary mycosis caused by Fusarium vasinfectum. Am J Respir Crit Care Med 1995; 152: 1379-1381.
42. Moreno-Ancillo A, Diaz-Pena JM, Ferrer A, et al. Allergic bronchopulmonary cladosporiosis in a child. J Allergy Clin Immunol 1996; 97: 714-715. (Pubitemid 26062774)
43. Ogawa H, Fujimura M, Tofuku Y. Allergic bronchopulmonary fungal disease caused by Saccharomyces cerevisiae. J Asthma 2004; 41: 223-228. (Pubitemid 38507105)
44. Ward GW, Jr., Woodfolk JA, Hayden ML, Jackson S, Platts-Mills TA. Treatment of late-onset asthma with f uconazole. J Allergy Clin Immunol 1999; 104: 541-546.
45. Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179: 11-18.
46. Abruzzo GK, Fromtling RA, Turnbull TA, Giltinan DM. Effects of bifonazole, f uconazole, itraconazole, and terbinaf ne on the chemiluminescence response of immune cells. J Antimicrob Chemother 1987; 20: 61-68. (Pubitemid 17100057)
47. Pawelec G, Jaschonek K, Ehninger G. The anti-fungal agent itra-conazole exerts immunosuppressive effects on alloreactivity but not on natural immunity in vitro. Int J Immunopharmacol 1991; 13: 875-879.
48. Pawelec G, Ehninger G, Rehbein A, Schaudt K, Jaschonek K. Comparison of the immunosuppressive activities of the antimycotic agents itraconazole, fluconazole, ketoconazole and miconazole on human T-cells. Int J Immunopharmacol 1991; 13: 299-304.
49. Kim JH, Ahn YK. The effects of itraconazole on the immune responses in ICR mice. J Toxicol Sci 1994; 19: 7-15. (Pubitemid 24104203)
50. Kanda N, Enomoto U, Watanabe S. Anti-mycotics suppress inter-leukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis. J Invest Dermatol 2001; 117: 1635-1646. (Pubitemid 34032798)
51. Ausaneya U, Kawada A, Aragane Y. Itraconazole suppresses an elicitation phase of a contact hypersensitivity reaction. J Invest Dermatol 2006; 126: 1028-1035.
52. Simitsopoulou M, Roilides E, Likartsis C, et al. Expression of immunomodulatory genes in human monocytes induced by voricon-azole in the presence of Aspergillus fumigatus. Antimicrob Agents Chemother 2007; 51: 1048-1054. (Pubitemid 46355294)
53. Agarwal R, Chakrabarti A. Epidemiology of Allergic Bronchopul-monary Aspergillosis. In: Pasqualotto AC (ed.), Aspergillosis: From Diagnosis to Prevention. New York: Springer; 2009: 671-688.
54. Agarwal R, Gupta D, Aggarwal AN, Behera D, Jindal SK. Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India. Chest 2006; 130: 442-448. (Pubitemid 44267011)
55. Agarwal R, Gupta D, Aggarwal AN, et al. Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients. Chest 2007; 132: 1183-1190. (Pubitemid 47620991)
56. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009; 135: 805-826.
57. Agarwal R, Chakrabarti A. Clinical manifestations and natural history of allergic bronchopulmonary aspergillosis. In: Pasqualotto AC, ed. Aspergillosis: From Diagnosis to Prevention. New York: Springer; 2009: 707-724.
58. Agarwal R, Gupta D, Aggarwal AN, et al. Clinical significance of decline in serum IgE levels in allergic bronchopulmonary aspergil-losis. Respir Med 2010; 104: 204-210.
59. Agarwal R, Hazarika B, Gupta D, et al. Aspergillus hypersensitivity in patients with chronic obstructive pulmonary disease: COPD as a risk factor for ABPA? Med Mycol 2010; In Press.
60. Agarwal R. Controversies in allergic bronchopulmonary aspergil-losis. Int J Respir Care 2010; In Press.
61. Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Aspergillus hyper-sensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis. Int J Tuberc Lung Dis 2009; 13: 936-944.
62. Schwartz HJ, Citron KM, Chester EH, et al. A comparison of the prevalence of sensitization to Aspergillus antigens among asthmatics in Cleveland and London. J Allergy Clin Immunol 1978; 62: 9-14. (Pubitemid 8391441)
63. Maurya V, Gugnani HC, Sarma PU, Madan T, Shah A. Sensitiza-tion to Aspergillus antigens and occurrence of allergic broncho-pulmonary aspergillosis in patients with asthma. Chest 2005; 127: 1252-1259. (Pubitemid 46224288)
64. Agarwal R, Nath A, Aggarwal AN, Gupta D, Chakrabarti A. Asper-gillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with acute severe asthma in a respiratory intensive care unit in North India. Mycoses 2010; 53: 138-143.
65. Porter P, Susarla SC, Polikepahad S, et al. Link between allergic asthma and airway mucosal infection suggested by proteinase-secreting household fungi. Mucosal Immunol 2009; 2: 504-517.
66. Gudmundsson G, Hunninghake GW. Interferon-gamma is necessary for the expression of hypersensitivity pneumonitis. J Clin Invest 1997; 99: 2386-2390. (Pubitemid 27227715)
67. Liang KL, Su MC, Jiang RS. Comparison of the skin test and ImmunoCAP system in the evaluation of mold allergy. J Chin Med Assoc 2006; 69: 3-6.
68. O'Driscoll BR, Powell G, Chew F, et al. Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy 2009; 39: 1677-1683.
69. Malo JL, Paquin R. Incidence of immediate sensitivity to Aspergillus fumigatus in a North American asthmatic population. Clin Allergy 1979; 9: 377-384. (Pubitemid 9245434)
70. Ownby DR. Diagnostic tests in allergy. In: Lieberman P, Anderson JA (eds), Allergic Diseases: Diagnosis and Treatment. 3rd ed. Totowa, NJ: Humana Press; 2007: 27-38.
71. Chakrabarti A, Sethi S, Raman DS, Behera D. Eight-year study of allergic bronchopulmonary aspergillosis in an Indian teaching hospital. Mycoses 2002; 45: 295-299. (Pubitemid 35279060)
72. Behera D, Guleria R, Jindal SK, Chakrabarti A, Panigrahi D. Allergic bronchopulmonary aspergillosis: a retrospective study of 35 cases. Indian J Chest Dis Allied Sci 1994; 36: 173-179.
73. Kurup VP. Aspergillus antigens: which are important? Med Mycol 2005; 43(Suppl. 1): S189-196. (Pubitemid 41038569)
74. Kurup VP, Banerjee B, Hemmann S, et al. Selected recombinant Aspergillus fumigatus allergens bind specifically to IgE in ABPA. Clin Exp Allergy 2000; 30: 988-993. (Pubitemid 30427040)
75. Crameri R, Hemmann S, Ismail C, Menz G, Blaser K. Disease-specific recombinant allergens for the diagnosis of allergic bronchopulmonary aspergillosis. Int Immunol 1998; 10: 1211-1216. (Pubitemid 28362696)
76. Crameri R. Recombinant Aspergillus fumigatus allergens: from the nucleotide sequences to clinical applications. Int Arch Allergy Immunol 1998; 115: 99-114. (Pubitemid 28048339)
77. Crameri R, Lidholm J, Gronlund H, et al. Automated specific IgE assay with recombinant allergens: evaluation of the recombinant Aspergillus fumigatus allergen I in the Pharmacia Cap System. Clin Exp Allergy 1996; 26: 1411-1419. (Pubitemid 27019797)
78. Nikolaizik WH, Moser M, Crameri R, et al. Identification of allergic bronchopulmonary aspergillosis in cystic f brosis patients by recombinant Aspergillus fumigatus I/a-specific serology. Am J Respir Crit Care Med 1995; 152: 634-639.
79. Hemmann S, Nikolaizik WH, Schoni MH, Blaser K, Crameri R. Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic f brosis patients with allergic bronchopulmo-nary aspergillosis or Aspergillus allergy. Eur J Immunol 1998; 28: 1155-1160. (Pubitemid 28156405)
80. Nikolaizik WH, Weichel M, Blaser K, Crameri R. Intracutaneous tests with recombinant allergens in cystic f brosis patients with allergic bronchopulmonary aspergillosis and Aspergillus allergy. Am J Respir Crit Care Med 2002; 165: 916-921. (Pubitemid 34774657)
81. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-1411.
82. Agarwal R, Khan A, Aggarwal AN, Gupta D. Is the SMART approach better than other treatment approaches for prevention of asthma exacerbations? A meta-analysis. Monaldi Arch Chest Dis 2009; 71: 161-169.
83. Brusselle G, Michils A, Louis R, et al. 'Real-life'effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009; 103: 1633-1642.
84. Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990; 26: 561-566. (Pubitemid 20346872)
85. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001; 51: 443-450. (Pubitemid 32852982)
86. Main KM, Skov M, Sillesen IB, et al. Cushing's syndrome due to pharmacological interaction in a cystic f brosis patient. Acta Paediatr 2002; 91: 1008-1011. (Pubitemid 35168419)
87. Skov M, Main KM, Sillesen IB, et al. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J 2002; 20: 127-133. (Pubitemid 34822934)